Introduction

Background

Pharmacotherapy of mental disorders has been developed for more than half century; however, the efficacy has been limited. Due to the diversity and heterogeneity of mental disorders, large and high-quality clinical trials are crucial to develop novel diagnostic and treatment strategies for mental disorders. Therefore, we set up “Consortium for Mental Disorders (CMD)”. The goals of this consortium are integrating research resources of mental disorders in Taiwan and assisting investigators in initiating and performing state-of-the-art, multi-center clinical trials.

 

Our Mission 

  1. To facilitate the "CMD" to be an excellent clinical trial consortium for mental disorders in Asia and all over the world.
  2. To attract international pharmaceutical and medical technological companies to conduct clinical trials in Taiwan.
  3. To help domestic pharmaceutical and medical technological companies to conduct clinical trials in Taiwan.
  4. To help investigators to conduct investigator-initiated trials for mental disorders domestically and internationally. 
  5. To promote new-drug and new medical technological development for the novel diagnostic assessment and treatment of mental disorders.

 

Contact Information

“Consortium for Mental Disorders (CMD)”

Principal Investigator : Professor Hsien-Yuan Lane

TEL:+886-4-22052121 ext. 1855

E-mail:hylane@gmail.com

 

Executive Secretary: Mr. Cheng-Yuan Chan

TEL:+886-4-22052121 ext. 7540

E-mail:max780110@gmail.com